№ files_lp_4_process_1_46878
File format: docx
Character count: 51969
File size: 765 KB
Year:
2020
Region / City:
Australia
Topic:
Pneumococcal Vaccination Recommendations
Document Type:
Public Consultation
Organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target Audience:
Healthcare professionals, general public, stakeholders in immunization policies
Period of Validity:
2020 and beyond
Approval Date:
Not specified
Date of Changes:
March 2020
Contextual Description:
Public consultation document outlining proposed changes to the recommended use of pneumococcal vaccines, aimed at improving vaccination guidelines and access for high-risk populations.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Organization / institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target audience:
Healthcare professionals involved in immunization
Period of validity:
From 5 January 2026 to 5 January 2029
Approval date:
5 January 2026
Amendment date:
2 June 2025, 16 December 2025
Description:
A document detailing the administration guidelines for the pneumococcal polysaccharide conjugate vaccine (PCV13, PCV15) for children under 2 years old in the UK.
Year:
2025
Region / city:
England
Topic:
Immunization
Document type:
Patient Group Direction (PGD)
Authoring body:
UK Health Security Agency (UKHSA)
Target audience:
Healthcare professionals involved in immunization programs
Period of validity:
17 December 2025 - 17 December 2028
Approval date:
9 December 2025
Review date:
17 July 2028
Expiry date:
17 December 2028
Publications gateway number:
GOV-16528
Reference number:
PPV23 PGD
Version:
5.00
Valid from:
1 September 2024
Review date:
1 September 2026
Expiry date:
1 March 2027
Vaccine:
23-valent pneumococcal polysaccharide vaccine (PPV23)
Programme:
National immunisation programme against pneumococcal disease
Target population:
Individuals aged 65 years and over and individuals aged 2 years and over in clinical risk groups
Geographical scope:
England
Legal framework:
Human Medicines Regulations 2012, Schedule 16 Part 2
Issuing organisation:
UK Health Security Agency
Developing body:
Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency
Authors:
Christina Wilson; Professor Shamez Ladhani; David Green
Approval status:
Ratified by the UKHSA Medicines Governance Committee
Document type:
Patient Group Direction
Year:
2021
Region / City:
Australia
Topic:
Pneumococcal vaccine submission
Document type:
Submission for listing on the National Immunisation Program
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Health professionals, regulatory bodies, policy makers
Period of validity:
Ongoing
Approval date:
16 July 2021 (FDA approval), 14 October 2021 (EMA recommendation)
Date of changes:
Not specified
Context:
A clinical submission for the inclusion of a 15-valent pneumococcal conjugate vaccine (PCV15) on the National Immunisation Program for adults at risk of pneumococcal disease.
Year:
2023
Region / city:
Australia
Subject:
Pneumococcal vaccine
Document type:
Submission
Organ / institution:
Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Pfizer Australia Pty Ltd
Target audience:
Healthcare professionals, public health policymakers
Period of validity:
Ongoing
Approval date:
27 April 2023 (FDA approval)
Amendment date:
20 December 2022 (TGA submission)
Background:
This document presents the submission for the 20-valent pneumococcal conjugate vaccine to be listed on the National Immunisation Program in Australia for specific paediatric populations.
Year:
2019
Region / City:
Australia
Topic:
Invasive Pneumococcal Disease, Vaccination, Disease Surveillance
Document Type:
Surveillance Report
Organization / Institution:
Communicable Diseases Network Australia
Author:
Kate Pennington, Enhanced Invasive Pneumococcal Disease Surveillance Working Group
Target Audience:
Public Health Officials, Healthcare Providers
Period of Validity:
1 April 2019 – 30 June 2019
Approval Date:
Not specified
Date of Changes:
Not specified
Description:
Report on invasive pneumococcal disease incidence, vaccination impact, and seasonal variations across Australia for the second quarter of 2019.
Year:
2023
Region / city:
Australia
Topic:
Pneumococcal vaccination
Document type:
Submission
Agency / organization:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Merck Sharp & Dohme (Australia) Pty Ltd
Target audience:
Healthcare professionals involved in immunization
Period of validity:
Not specified
Approval date:
Expected by 30 April 2023
Date of changes:
9 February 2023
Year:
2016
Region / City:
Australia
Theme:
Pneumococcal disease prevention
Document Type:
Submission
Organization / Institution:
Pfizer Australia Pty Ltd
Author:
Pfizer Australia Pty Ltd
Target Audience:
Healthcare professionals, policymakers, public health authorities
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2014
Region / City:
United States
Subject:
Pneumococcal immunization and health reminders
Document Type:
Installation and Setup Guide
Institution:
Department of Veterans Affairs
Author:
Not specified
Target Audience:
Healthcare professionals in the Veterans Affairs system
Validity Period:
Ongoing updates for system usage
Approval Date:
February 2014
Modification Date:
Not specified
Document type:
Supplementary tables
Subject:
ICD-9-CM diagnostic codes for pneumococcal diseases and comorbidities
Disease categories:
Invasive pneumococcal disease (IPD), non-IPD pneumococcal infections, acute otitis media (AOM), otitis media with effusion (OME), AOM complications
Classification system:
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM)
Content structure:
Disease type, clinical condition, ICD-9-CM code or code combinations, description
Clinical focus:
Pneumococcal infections and related complications
Additional dataset:
ICD-9-CM codes for prior comorbidities
Comorbidity categories:
Neurological, cardiovascular, lung, liver, kidney, metabolic, immunological conditions
Purpose:
Study cohort identification using diagnostic codes
Abbreviations:
IPD (Invasive Pneumococcal Diseases), PNI (Pneumococcal Infections), AOM (Acute Otitis Media), OME (Otitis Media with Effusion)
Year:
2025
Region / city:
Global
Topic:
Vaccine Policy, Maternal Health, Group B Streptococcus
Document type:
WHO Guidance
Institution:
World Health Organization (WHO)
Author:
WHO ECVP
Target audience:
Policymakers, Vaccine Developers, Public Health Authorities
Period of validity:
Ongoing
Approval date:
March 11, 2025
Date of changes:
Not specified
Year:
2024
Region / city:
Global
Topic:
COVID-19 Vaccines
Document type:
Report
Author:
World Health Organization (WHO)
Target audience:
Health professionals, regulatory authorities
Approval date:
16 January 2024
Modification date:
N/A
Contextual description:
A report listing COVID-19 vaccines evaluated under the WHO EUL/PQ process, including details on manufacturers, vaccine types, shelf lives, and approval dates.
Year:
2026
Jurisdiction:
Victoria, Australia
Document type:
Report form
Subject:
Vaccine cold chain breach reporting
Issuing authority:
Department of Health, Victorian Government
Program:
Immunisation Program
Applicable vaccines:
Government funded vaccines and immunisation products
Target users:
Immunisation providers
Scope:
Cold chain breach events excluding delivery incidents
Temperature range reference:
+2°C to +8°C
Reporting method:
Email submission to Immunisation Program
Publication date:
January 2026
Publisher:
State of Victoria, Australia
Copyright holder:
Department of Health, Victoria
Note:
Year
Region / City:
Alabama
Theme:
Vaccine management, immunization program
Document Type:
Vaccine management plan
Organization / Institution:
Alabama Department of Public Health (ADPH)
Author:
Alabama Department of Public Health (ADPH)
Target Audience:
VFC providers, immunization staff
Effective Period:
Ongoing
Year:
2024
Region / City:
Victoria, Australia
Topic:
Immunisation
Document Type:
Official Information
Author:
Department of Health, State of Victoria
Target Audience:
Healthcare professionals, parents, and individuals requiring immunisation information
Period of Validity:
Not specified
Approval Date:
August 2024
Date of Changes:
Not specified
Year:
2023
Region / City:
Massachusetts
Topic:
Meningococcal disease, Vaccination requirements
Document type:
Health advisory
Institution:
Massachusetts Department of Public Health
Author:
Massachusetts Department of Public Health
Target audience:
College and residential school students, Parents and legal guardians
Period of validity:
Ongoing
Approval date:
Not specified
Amendment date:
Not specified
Year:
2025
Region / city:
Victoria, Australia
Subject:
Immunisation, Vaccines
Document type:
Health guideline
Organ / institution:
Department of Health and Human Services, Victorian Government
Author:
Victorian Government
Target audience:
Healthcare professionals, general public, parents, caregivers
Period of validity:
Until 2025
Approval date:
July 2025
Date of amendments:
Not specified
Year:
2023
Region / city:
Australia
Topic:
COVID-19 vaccines
Document type:
Clinical guidance
Organization / institution:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target audience:
Healthcare professionals, general public
Period of validity:
Ongoing
Approval date:
October 2023
Date of changes:
Multiple updates since February 2021
Year:
2025
Region / City:
Northern Ireland
Topic:
COVID-19 vaccination, mRNA vaccines
Document Type:
Protocol
Organization / Institution:
Strategic Planning and Performance Group (SPPG), Public Health Agency (PHA)
Author:
Dr. Louise Herron, Mrs. Deirdre Ward, Mrs. Kathryn Turner
Target Audience:
Healthcare professionals administering COVID-19 mRNA vaccines
Period of Validity:
3 April 2025 to 30 June 2025
Approval Date:
3 April 2025
Note:
Change History
Version 1.0:
New national protocol for COVID-19 vaccines (adults) - 5 April 2024
Version 2.0:
Updated to reflect change in vaccine antigenic content - 16 September 2024
Version 3.0:
Updated eligibility criteria for Spring 2025 - 6 March 2025
Year:
2025
Region / City:
Wisconsin
Theme:
Public Health, Vaccination Programs
Document Type:
Provider Agreement
Organization:
Department of Health Services, Division of Public Health
Author:
Department of Health Services
Target Audience:
Health Care Providers, Medical Directors
Period of Validity:
Annual Enrollment
Approval Date:
Not specified
Date of Amendments:
Not specified